Sign up
Quantellect · Analysts · Analyst Profile
Q Score Rank#165 of 388

Mitchell Kapoor

HC Wainwright & Co. · Equity Research Analyst
EstablishedRating since 2022No new ratings since Jul 2025

Analyst rating accuracy & track record

Mitchell Kapoor is an equity research analyst at HC Wainwright & Co.. Quantellect has scored 114 of their stock calls across 20 companies. Their picks beat their sector 34% of the time over the next 12 months, and their price targets were reached 27% of the time within a year.

Win % vs sector
34%
PT Hit % (12mo)
27%
Avg sector-excess
−3.8%
Scored calls
114
Tickers
20
Tier
Established

Track record

Quantellect has scored 114 of Mitchell Kapoor's stock calls across 20 companies, dating back to 2022. Their rated stocks beat their own sector 34% of the time over the next 12 months. On a typical call, a Kapoor pick returned −3.8% more than its sector over the following year.

Of the scored calls, 114 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
KRROKorro Bio, Inc.
Buy$100.00Jul 2025−54.2%Miss
LEGNLegend Biotech Corp
Buy$75.00Jul 2025−70.3%Miss
LEGNLegend Biotech Corp
Buy$75.00Jul 2025−50.7%Miss
TYRATyra Biosciences Inc
Buy$30.00Jul 2025+173.2%Hit
SMMTSummit Therapeutics PLC
Buy$44.00Jul 2025−55.8%Miss
CRSPCrispr Therapeutics AG
Buy$65.00Jun 2025−5.0%Hit
TILInstil Bio Inc.
Buy$125.00Jun 2025−91.4%Miss
AVTXAvalo Therapeutics Inc
Buy$15.00Jun 2025+205.3%Hit
HALOHalozyme Therapeutics Inc
Buy$72.00May 2025+4.0%Hit
KYTXKyverna Therapeutics, Inc. Common Stock
Buy$5.00May 2025+221.7%Hit
TILInstil Bio Inc.
Buy$125.00May 2025−80.8%Miss
TILInstil Bio Inc.
Buy$105.00May 2025−78.1%Miss
CTMXCytomX Therapeutics Inc
Buy$5.00May 2025+68.5%Hit
LXEOLexeo Therapeutics, Inc. Common Stock
Buy$15.00May 2025+32.8%Miss
CTMXCytomX Therapeutics Inc
Buy$5.00May 2025+66.9%Hit
KRROKorro Bio, Inc.
Buy$100.00May 2025−32.6%Miss
EDITEditas Medicine Inc
Buy$3.00Apr 2025+92.3%Hit
HALOHalozyme Therapeutics Inc
Buy$72.00Apr 2025+1.1%Hit
ALMSAlumis Inc
Buy$14.00Apr 2025+439.9%Hit
RNACCartesian Therapeutics Inc.
Buy$40.00Apr 2025−53.0%Miss
LXEOLexeo Therapeutics, Inc. Common Stock
Buy$23.00Apr 2025+163.1%Miss
IPSCCentury Therapeutics Inc
Buy$2.00Apr 2025+388.7%Hit
RANIRani Therapeutics Holdings Inc
Buy$9.00Apr 2025−41.5%Miss
TYRATyra Biosciences Inc
Buy$30.00Mar 2025+335.1%Hit
ALMSAlumis Inc
Buy$15.00Mar 2025+457.7%Hit
LXEOLexeo Therapeutics, Inc. Common Stock
Buy$23.00Mar 2025+35.1%Miss
ABEOAbeona Therapeutics Inc
Buy$15.00Mar 2025−14.8%Miss
KRROKorro Bio, Inc.
Buy$115.00Mar 2025−55.6%Miss
RLYBRallybio Corp
Buy$5.00Mar 2025+60.6%Miss
RNACCartesian Therapeutics Inc.
Buy$40.00Mar 2025−53.9%Miss
ALMSAlumis Inc
Buy$19.00Mar 2025+419.2%Hit
ALMSAlumis Inc
Buy$19.00Mar 2025+479.9%Hit
HALOHalozyme Therapeutics Inc
BuyMar 2025+6.4%
TILInstil Bio Inc.
Buy$110.00Mar 2025−60.4%Miss
ABEOAbeona Therapeutics Inc
Buy$15.00Feb 2025−17.8%Miss
TYRATyra Biosciences Inc
Buy$30.00Feb 2025+120.3%Hit
RLYBRallybio Corp
Buy$5.00Feb 2025−32.5%Miss
ALMSAlumis Inc
Buy$19.00Feb 2025+433.2%Hit
RNACCartesian Therapeutics Inc.
Buy$45.00Jan 2025−69.9%Miss
IPSCCentury Therapeutics Inc
Buy$5.00Jan 2025+142.0%Miss
TYRATyra Biosciences Inc
Buy$30.00Jan 2025+66.8%Hit
RLYBRallybio Corp
Buy$5.00Jan 2025−34.7%Miss
RLYBRallybio Corp
Buy$5.00Dec 2024−47.0%Miss
KRROKorro Bio, Inc.
Buy$115.00Nov 2024−97.3%Miss
RLYBRallybio Corp
Buy$5.00Nov 2024−48.2%Miss
RANIRani Therapeutics Holdings Inc
Buy$9.00Nov 2024−23.2%Miss
TILInstil Bio Inc.
Buy$110.00Nov 2024−60.4%Miss
TILInstil Bio Inc.
Buy$110.00Nov 2024−54.5%Miss
LXEOLexeo Therapeutics, Inc. Common Stock
Buy$23.00Nov 2024+27.0%Miss
KRROKorro Bio, Inc.
Buy$115.00Nov 2024−94.5%Miss
Go to

Mitchell Kapoor: analyst track record FAQ

Is Mitchell Kapoor a good stock analyst?

Yes, by track record. Mitchell Kapoor ranks number 165 of 388 of the analysts Quantellect scores, with a Q Score of 38 out of 100. Past results do not guarantee future ones.

What is Mitchell Kapoor's win rate?

Mitchell Kapoor's win rate is 34%. Across 114 scored calls, their rated stocks beat their sector 34% of the time over the next 12 months. On a typical call they returned −3.8% more than the sector.

What stocks and sectors does Mitchell Kapoor cover?

Mitchell Kapoor covers 20 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Mitchell Kapoor's price targets accurate?

Mitchell Kapoor's price targets are reached within 12 months 27% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Mitchell Kapoor's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Mitchell Kapoor rank among Wall Street analysts?

Mitchell Kapoor ranks number 165 of 388 by Q Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.